New breast cancer drug under Real-World scrutiny in 300-Patient study
NCT ID NCT07358182
Summary
This study is observing how well the drug trastuzumab-rezetecan works and how safe it is for people with HER2-positive or HER2-low breast cancer in real-world medical settings. It will follow 300 patients who are already scheduled to receive this treatment as part of their regular care. Researchers will track how patients respond to the treatment and monitor any side effects to understand its real-world performance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.